Clarametyx Biosciences Inc. is a clinical-stage biotechnology company developing immune-enabling biologic therapies to combat life-threatening infections. The company’s innovative platform targets bacterial biofilms—the protective barriers that shield pathogens—enhancing the immune system’s ability to clear infections effectively. By focusing on this critical mechanism, Clarametyx aims to address unmet medical needs in infectious diseases and offer new treatment options where conventional therapies may fail. With a commitment to scientific innovation, rigorous clinical development, and patient-focused solutions, Clarametyx collaborates with healthcare partners to accelerate the delivery of safe, effective therapies, advancing the fight against serious bacterial infections worldwide.